Lauren Merendino
CIK 1855298 · Chief Commercial Officer · last filed 2026-04-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
18
Lifetime Open-Market Net
-$343.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Chief Commercial Officer | 0 | $21.53 | $0 | -$150.7K | 7 | 2026-04-23 |
| ESSA Pharma Inc. (EPIX) Delisted | Director | — | $0.20 | — | $0 | 1 | 2024-03-28 |
| Myovant Sciences Ltd. (MYOV) Delisted | Chief Commercial Officer | 147,747 | $26.98 | $3.99M | -$192.5K | 7 | 2023-03-10 |
Recent Filings · Page 2 of 2
18 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-28 | ESSA Pharma Inc. (EPIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-10 | Myovant Sciences Ltd. (MYOV) Delisted | Disp (D) | −169,538 | $0 | EDGAR |
| 2023-01-20 | Myovant Sciences Ltd. (MYOV) Delisted | Sell (S) | −2,008 | -$54.0K | EDGAR |
| 2022-10-20 | Myovant Sciences Ltd. (MYOV) Delisted | Sell (S) | −1,703 | -$42.9K | EDGAR |
| 2022-07-20 | Myovant Sciences Ltd. (MYOV) Delisted | Sell (S) | −1,704 | -$21.9K | EDGAR |
| 2022-04-21 | Myovant Sciences Ltd. (MYOV) Delisted | Sell (S) | −7,049 | -$73.7K | EDGAR |
| 2022-04-19 | Myovant Sciences Ltd. (MYOV) Delisted | Grant (A) | +103,703 | $0 | EDGAR |
| 2021-04-19 | Myovant Sciences Ltd. (MYOV) Delisted | Grant (A) | +78,299 | $0 | EDGAR |
Showing 11–18 of 18
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.